ENANTA PHARMACEUTICALS, INC. Patent applications |
Patent application number | Title | Published |
20140341851 | NOVEL BENZIMIDAZOLE DERIVATIVES - The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 11-20-2014 |
20140316143 | PROCESSES FOR THE PREPARATION OF NOVEL BENZIMIDAZOLE DERIVATIVES - The present invention relates to processes and intermediates for the preparation of novel benzimidazole derivatives, especially in the synthesis of hepatitis C virus NS5A inhibitors. In particular, the present invention relates to processes and intermediates for the preparation of compounds of formulae (I-a): | 10-23-2014 |
20140308243 | HEPATITIS C VIRUS INHIBITORS - The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, esters, or prodrugs thereof: | 10-16-2014 |
20140219958 | 5, 6-D2 URIDINE NUCLEOSIDE/TIDE DERIVATIVES - In one aspect, the invention provides compounds represented by Formula I, | 08-07-2014 |
20140194350 | MACROCYCLIC PROLINE DERIVED HCV SERINE PROTEASE INHIBITORS - The present invention discloses compounds of Formula I or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 07-10-2014 |
20140193363 | NOVEL BENZIMIDAZOLE DERIVATIVES - The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 07-10-2014 |
20140187793 | PROCESSES FOR THE PREPARATION OF 5-AZASPIRO[2.4]HEPTANE-6-CARBOXYLIC ACID AND ITS DERIVATIVES - The present invention relates generally to an improved process for the preparation of 5-azaspiro[2.4]heptane-6-carboxylic acid and its derivatives which are useful intermediates in the synthesis of biologically active molecules, especially in the synthesis of hepatits C virus NS5A inhibitors. In particular, the present invention relates to processes and intermediates for the preparation of compounds of formulae (Ia), (Ib) and (Ic): | 07-03-2014 |
20140187780 | 6,11-BRIDGED BIARYL MACROLIDES - The present invention discloses compounds of formula I, II or X, or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 07-03-2014 |
20140154208 | Novel [N-Me-4-hydroxyleucine]-9-Cyclosporin Analogues for Treatment and Prevention of Hepatitis C Infection - The present invention relates to novel cyclosporine analogues having antiviral activity against HCV and useful in the treatment of HCV infections. More particularly, the invention relates to novel cyclosporine analogue compounds, compositions containing such compounds and methods for using the same, as well as processes for making such compounds. | 06-05-2014 |
20140148573 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS - The present invention relates to novel macrocyclic compounds and methods of treating a hepatitis C infection in a subject in need of such therapy with said macrocyclic compounds. The present invention further relates to pharmaceutical compositions comprising the compounds of the present invention, or pharmaceutically acceptable salts, esters, or prodrugs thereof, in combination with a pharmaceutically acceptable carrier or excipient. | 05-29-2014 |
20140135485 | 6-11 BICYCLIC KETOLIDE DERIVATIVES - The present invention discloses compounds of formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 05-15-2014 |
20140073797 | PROCESSES FOR THE PREPARATION OF 2-FLUORO 6-11 BICYCLIC ERYTHROMYCIN DERIVATIVES - The present invention relates to processes and intermediates for the preparation of 2-fluoro 6-11 bicyclic erythromycin derivatives. In particular, the present invention relates to processes and intermediates for the preparation of a compound of formula (X-c): | 03-13-2014 |
20130315864 | MACROCYCLIC NUCLEOSIDE PHOSPHORAMIDATE DERIVATIVES - The present invention provides nucleoside phosphoramidate compounds of Formula I, | 11-28-2013 |
20130295049 | LINKED DIBENZIMIDAZOLE ANTIVIRALS - The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 11-07-2013 |
20130231298 | ANTI-BACTERIAL ACTIVITY OF 9-HYDROXY DERIVATIVES OF 6,11-BICYCLOLIDES - The present invention discloses compounds of formula (I) or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 09-05-2013 |
20130183267 | CYCLOSPORIN ANALOGUES FOR PREVENTING OR TREATING HEPATITIS C INFECTION - The present invention relates to cyclosporin analogues having antiviral activity against HCV and useful in the treatment of HCV infections. More particularly, the invention relates to novel cyclosporin analogue compounds, compositions containing such compounds and methods for using the same, as well as processes for making such compounds. | 07-18-2013 |
20130165641 | 6,11-BRIDGED BIARYL MACROLIDES - The present invention discloses compounds of formula I, II or X, or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 06-27-2013 |
20130144036 | QUINOXALINE-CONTAINING COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS - The present invention discloses compounds of formula I and II or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 06-06-2013 |
20120196792 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS - The present invention relates to novel macrocyclic compounds and methods of treating a hepatitis C infection in a subject in need of such therapy with said macrocyclic compounds. The present invention further relates to pharmaceutical compositions comprising the compounds of the present invention, or pharmaceutically acceptable salts, esters, or prodrugs thereof, in combination with a pharmaceutically acceptable carrier or excipient. | 08-02-2012 |
20120101031 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS - The present invention relates to novel macrocyclic compounds and methods of treating a hepatitis C infection in a subject in need of such therapy with said macrocyclic compounds. The present invention further relates to pharmaceutical compositions comprising the compounds of the present invention, or pharmaceutically acceptable salts, esters, or prodrugs thereof, in combination with a pharmaceutically acceptable carrier or excipient. | 04-26-2012 |